

Global iPSC-Derived Islet Cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G25C875AEA05EN.html>

Date: August 2026

Pages: 87

Price: US\$ 3,480.00 (Single User License)

ID: G25C875AEA05EN

Abstracts

According to our (Global Info Research) latest study, the global iPSC-Derived Islet Cell Therapy market size was valued at US\$ 51.45 million in 2025 and is forecast to a readjusted size of US\$ 1058 million by 2032 with a CAGR of 53.7% during review period.

iPSC-Derived Islet Cell Therapy refers to regenerative medicine products in which somatic cells from autologous patients or donors are reprogrammed into induced pluripotent stem cells (iPSCs), and subsequently differentiated into islet-like cell clusters, β -cell-enriched populations, or engineered islets composed of multiple endocrine cell types. These products are designed to replace or restore impaired pancreatic islet function in patients with diabetes. They are typically developed as injectable cell suspensions, islet-like cell cluster grafts, or implantable constructs combined with immune isolation devices or bioprinted scaffolds. Key development priorities include glucose-responsive insulin secretion, cellular composition consistency, control of residual undifferentiated cells, immune rejection management, scalable GMP manufacturing, and long-term safety. The overall gross margin is approximately 60%.

Demand for this therapy is primarily driven by the long-term burden of diabetes management, the shortage of donor-derived islets, and the inability of exogenous insulin therapy to restore endogenous glucose regulation. Emerging clinical and preclinical data are gradually expanding islet replacement therapy from a small population of high-risk type 1 diabetes patients toward a broader insulin-dependent diabetes population. As a result, hospitals, research institutions, and large pharmaceutical companies are increasingly interested in standardized, scalable regenerative islet products.

Product development is focused on three main technological pathways: first, autologous iPSC-derived islet cell therapy, which emphasizes immune compatibility and personalized efficacy; second, allogeneic off-the-shelf islet cell banks, which prioritize scalable manufacturing, standardized quality release, and cost efficiency; and third, integrated approaches combining gene-edited hypoimmunogenic cells, immune isolation devices, and bioprinted scaffolds, aiming to reduce or eliminate the need for long-term immunosuppression. Procurement and partnership evaluations typically focus on cell purity, β -cell proportion, glucose-stimulated insulin secretion, release testing systems, cryostability, implant site compatibility, and long-term clinical durability.

Regionally, the United States and Europe are advancing through collaboration between large pharmaceutical companies, cell therapy developers, and device platform providers. China and Japan are also progressing rapidly, supported by strong iPSC technology foundations, active clinical research ecosystems, and favorable regenerative medicine policies. Key opportunities lie in GMP differentiation processes, master cell banks, immune protection strategies, implantable delivery systems, and companion diagnostic tools. Major risks include tumorigenicity, immune rejection, uncertain long-term efficacy, manufacturing scale-up challenges, pricing and reimbursement constraints, and regulatory approval timelines.

Report Scope

This report is a detailed and comprehensive analysis for global iPSC-Derived Islet Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global iPSC-Derived Islet Cell Therapy market size and forecasts, in consumption value (\$ Million), 2021-2032

Global iPSC-Derived Islet Cell Therapy market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global iPSC-Derived Islet Cell Therapy market size and forecasts, by Type and by

Application, in consumption value (\$ Million), 2021-2032

Global iPSC-Derived Islet Cell Therapy market shares of main players, in revenue (\$ Million), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for iPSC-Derived Islet Cell Therapy

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global iPSC-Derived Islet Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Reprogenix Bioscience, Sana Biotechnology, Century Therapeutics, Evotec, Sernova, Aspect Biosystems, Novo Nordisk, Allele Biotechnology, SCM Lifescience, Creative Medical Technology, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

iPSC-Derived Islet Cell Therapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Autologous iPSC-Derived Islet Cell Therapy

HLA-Matched Allogeneic iPSC-Derived Islet Cell Therapy

Universal Allogeneic iPSC-Derived Islet Cell Therapy

Market segment by Cell Composition

Beta Cell-Enriched Clusters

Islet-Like Clusters

Endocrine Subtype-Complete Islets

Pancreatic Islet Organoids

Market segment by Immune Protection Strategy

Immunosuppression-Dependent Therapy

Encapsulation-Protected Therapy

Hypoimmune Gene-Edited Therapy

Autologous Immune-Matched Therapy

Market segment by Transplantation Site

Portal Vein or Liver Site

Subcutaneous Site

Intramuscular Site

Omental Site

Other Implantation Sites

Market segment by Application

Type 1 Diabetes

Type 2 Diabetes

Pancreatogenic Diabetes

Monogenic or Special Diabetes

Preclinical Research

Other

Market segment by players, this report covers

Reprogenix Bioscience

Sana Biotechnology

Century Therapeutics

Evotec

Sernova

Aspect Biosystems

Novo Nordisk

Allele Biotechnology

SCM Lifescience

Creative Medical Technology

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Chapter Outline

Chapter 1, to describe iPSC-Derived Islet Cell Therapy product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of iPSC-Derived Islet Cell Therapy, with revenue, gross margin, and global market share of iPSC-Derived Islet Cell Therapy from 2021 to 2026.

Chapter 3, the iPSC-Derived Islet Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026. and iPSC-Derived Islet Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of iPSC-Derived Islet Cell Therapy.

Chapter 13, to describe iPSC-Derived Islet Cell Therapy research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of iPSC-Derived Islet Cell Therapy by Type

1.3.1 Overview: Global iPSC-Derived Islet Cell Therapy Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Type in 2025

1.3.3 Autologous iPSC-Derived Islet Cell Therapy

1.3.4 HLA-Matched Allogeneic iPSC-Derived Islet Cell Therapy

1.3.5 Universal Allogeneic iPSC-Derived Islet Cell Therapy

1.4 Classification of iPSC-Derived Islet Cell Therapy by Cell Composition

1.4.1 Overview: Global iPSC-Derived Islet Cell Therapy Market Size by Cell Composition: 2021 Versus 2025 Versus 2032

1.4.2 Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Cell Composition in 2025

1.4.3 Beta Cell-Enriched Clusters

1.4.4 Islet-Like Clusters

1.4.5 Endocrine Subtype-Complete Islets

1.4.6 Pancreatic Islet Organoids

1.5 Classification of iPSC-Derived Islet Cell Therapy by Immune Protection Strategy

1.5.1 Overview: Global iPSC-Derived Islet Cell Therapy Market Size by Immune Protection Strategy: 2021 Versus 2025 Versus 2032

1.5.2 Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Immune Protection Strategy in 2025

1.5.3 Immunosuppression-Dependent Therapy

1.5.4 Encapsulation-Protected Therapy

1.5.5 Hypoimmune Gene-Edited Therapy

1.5.6 Autologous Immune-Matched Therapy

1.6 Classification of iPSC-Derived Islet Cell Therapy by Transplantation Site

1.6.1 Overview: Global iPSC-Derived Islet Cell Therapy Market Size by Transplantation Site: 2021 Versus 2025 Versus 2032

1.6.2 Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Transplantation Site in 2025

1.6.3 Portal Vein or Liver Site

1.6.4 Subcutaneous Site

- 1.6.5 Intramuscular Site
- 1.6.6 Omental Site
- 1.6.7 Other Implantation Sites
- 1.7 Global iPSC-Derived Islet Cell Therapy Market by Application
 - 1.7.1 Overview: Global iPSC-Derived Islet Cell Therapy Market Size by Application: 2021 Versus 2025 Versus 2032
 - 1.7.2 Type 1 Diabetes
 - 1.7.3 Type 2 Diabetes
 - 1.7.4 Pancreatogenic Diabetes
 - 1.7.5 Monogenic or Special Diabetes
 - 1.7.6 Preclinical Research
 - 1.7.7 Other
- 1.8 Global iPSC-Derived Islet Cell Therapy Market Size & Forecast
- 1.9 Global iPSC-Derived Islet Cell Therapy Market Size and Forecast by Region
 - 1.9.1 Global iPSC-Derived Islet Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
 - 1.9.2 Global iPSC-Derived Islet Cell Therapy Market Size by Region, (2021-2032)
 - 1.9.3 North America iPSC-Derived Islet Cell Therapy Market Size and Prospect (2021-2032)
 - 1.9.4 Europe iPSC-Derived Islet Cell Therapy Market Size and Prospect (2021-2032)
 - 1.9.5 Asia-Pacific iPSC-Derived Islet Cell Therapy Market Size and Prospect (2021-2032)
 - 1.9.6 South America iPSC-Derived Islet Cell Therapy Market Size and Prospect (2021-2032)
 - 1.9.7 Middle East & Africa iPSC-Derived Islet Cell Therapy Market Size and Prospect (2021-2032)

2 COMPANY PROFILES

- 2.1 Reprogenix Bioscience
 - 2.1.1 Reprogenix Bioscience Details
 - 2.1.2 Reprogenix Bioscience Major Business
 - 2.1.3 Reprogenix Bioscience iPSC-Derived Islet Cell Therapy Product and Solutions
 - 2.1.4 Reprogenix Bioscience iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.1.5 Reprogenix Bioscience Recent Developments and Future Plans
- 2.2 Sana Biotechnology
 - 2.2.1 Sana Biotechnology Details
 - 2.2.2 Sana Biotechnology Major Business

- 2.2.3 Sana Biotechnology iPSC-Derived Islet Cell Therapy Product and Solutions
- 2.2.4 Sana Biotechnology iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Sana Biotechnology Recent Developments and Future Plans
- 2.3 Century Therapeutics
 - 2.3.1 Century Therapeutics Details
 - 2.3.2 Century Therapeutics Major Business
 - 2.3.3 Century Therapeutics iPSC-Derived Islet Cell Therapy Product and Solutions
 - 2.3.4 Century Therapeutics iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.3.5 Century Therapeutics Recent Developments and Future Plans
- 2.4 Evotec
 - 2.4.1 Evotec Details
 - 2.4.2 Evotec Major Business
 - 2.4.3 Evotec iPSC-Derived Islet Cell Therapy Product and Solutions
 - 2.4.4 Evotec iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.4.5 Evotec Recent Developments and Future Plans
- 2.5 Sernova
 - 2.5.1 Sernova Details
 - 2.5.2 Sernova Major Business
 - 2.5.3 Sernova iPSC-Derived Islet Cell Therapy Product and Solutions
 - 2.5.4 Sernova iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.5.5 Sernova Recent Developments and Future Plans
- 2.6 Aspect Biosystems
 - 2.6.1 Aspect Biosystems Details
 - 2.6.2 Aspect Biosystems Major Business
 - 2.6.3 Aspect Biosystems iPSC-Derived Islet Cell Therapy Product and Solutions
 - 2.6.4 Aspect Biosystems iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.6.5 Aspect Biosystems Recent Developments and Future Plans
- 2.7 Novo Nordisk
 - 2.7.1 Novo Nordisk Details
 - 2.7.2 Novo Nordisk Major Business
 - 2.7.3 Novo Nordisk iPSC-Derived Islet Cell Therapy Product and Solutions
 - 2.7.4 Novo Nordisk iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.7.5 Novo Nordisk Recent Developments and Future Plans

2.8 Allele Biotechnology

2.8.1 Allele Biotechnology Details

2.8.2 Allele Biotechnology Major Business

2.8.3 Allele Biotechnology iPSC-Derived Islet Cell Therapy Product and Solutions

2.8.4 Allele Biotechnology iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.8.5 Allele Biotechnology Recent Developments and Future Plans

2.9 SCM Lifescience

2.9.1 SCM Lifescience Details

2.9.2 SCM Lifescience Major Business

2.9.3 SCM Lifescience iPSC-Derived Islet Cell Therapy Product and Solutions

2.9.4 SCM Lifescience iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.9.5 SCM Lifescience Recent Developments and Future Plans

2.10 Creative Medical Technology

2.10.1 Creative Medical Technology Details

2.10.2 Creative Medical Technology Major Business

2.10.3 Creative Medical Technology iPSC-Derived Islet Cell Therapy Product and Solutions

2.10.4 Creative Medical Technology iPSC-Derived Islet Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.10.5 Creative Medical Technology Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global iPSC-Derived Islet Cell Therapy Revenue and Share by Players (2021-2026)

3.2 Market Share Analysis (2025)

3.2.1 Market Share of iPSC-Derived Islet Cell Therapy by Company Revenue

3.2.2 Top 3 iPSC-Derived Islet Cell Therapy Players Market Share in 2025

3.2.3 Top 6 iPSC-Derived Islet Cell Therapy Players Market Share in 2025

3.3 iPSC-Derived Islet Cell Therapy Market: Overall Company Footprint Analysis

3.3.1 iPSC-Derived Islet Cell Therapy Market: Region Footprint

3.3.2 iPSC-Derived Islet Cell Therapy Market: Company Product Type Footprint

3.3.3 iPSC-Derived Islet Cell Therapy Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global iPSC-Derived Islet Cell Therapy Consumption Value and Market Share by Type (2021-2026)

4.2 Global iPSC-Derived Islet Cell Therapy Market Forecast by Type (2027-2032)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Application (2021-2026)

5.2 Global iPSC-Derived Islet Cell Therapy Market Forecast by Application (2027-2032)

6 NORTH AMERICA

6.1 North America iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)

6.2 North America iPSC-Derived Islet Cell Therapy Market Size by Application (2021-2032)

6.3 North America iPSC-Derived Islet Cell Therapy Market Size by Country

6.3.1 North America iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2032)

6.3.2 United States iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

6.3.3 Canada iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

6.3.4 Mexico iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

7 EUROPE

7.1 Europe iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)

7.2 Europe iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2032)

7.3 Europe iPSC-Derived Islet Cell Therapy Market Size by Country

7.3.1 Europe iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2032)

7.3.2 Germany iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

7.3.3 France iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

7.3.4 United Kingdom iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

7.3.5 Russia iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

7.3.6 Italy iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

8 ASIA-PACIFIC

8.1 Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)

8.2 Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2032)

8.3 Asia-Pacific iPSC-Derived Islet Cell Therapy Market Size by Region

8.3.1 Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Region (2021-2032)

8.3.2 China iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

8.3.3 Japan iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

8.3.4 South Korea iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

8.3.5 India iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

8.3.6 Southeast Asia iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

8.3.7 Australia iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

9 SOUTH AMERICA

9.1 South America iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)

9.2 South America iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2032)

9.3 South America iPSC-Derived Islet Cell Therapy Market Size by Country

9.3.1 South America iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2032)

9.3.2 Brazil iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

9.3.3 Argentina iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)

10.2 Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2032)

10.3 Middle East & Africa iPSC-Derived Islet Cell Therapy Market Size by Country

10.3.1 Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by

Country (2021-2032)

10.3.2 Turkey iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

10.3.3 Saudi Arabia iPSC-Derived Islet Cell Therapy Market Size and Forecast
(2021-2032)

10.3.4 UAE iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

11 MARKET DYNAMICS

11.1 iPSC-Derived Islet Cell Therapy Market Drivers

11.2 iPSC-Derived Islet Cell Therapy Market Restraints

11.3 iPSC-Derived Islet Cell Therapy Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 iPSC-Derived Islet Cell Therapy Industry Chain

12.2 iPSC-Derived Islet Cell Therapy Upstream Analysis

12.3 iPSC-Derived Islet Cell Therapy Midstream Analysis

12.4 iPSC-Derived Islet Cell Therapy Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global iPSC-Derived Islet Cell Therapy Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global iPSC-Derived Islet Cell Therapy Consumption Value by Cell Composition, (USD Million), 2021 & 2025 & 2032

Table 3. Global iPSC-Derived Islet Cell Therapy Consumption Value by Immune Protection Strategy, (USD Million), 2021 & 2025 & 2032

Table 4. Global iPSC-Derived Islet Cell Therapy Consumption Value by Transplantation Site, (USD Million), 2021 & 2025 & 2032

Table 5. Global iPSC-Derived Islet Cell Therapy Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 6. Global iPSC-Derived Islet Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)

Table 7. Global iPSC-Derived Islet Cell Therapy Consumption Value by Region (2027-2032) & (USD Million)

Table 8. Reprogenix Bioscience Company Information, Head Office, and Major Competitors

Table 9. Reprogenix Bioscience Major Business

Table 10. Reprogenix Bioscience iPSC-Derived Islet Cell Therapy Product and Solutions

Table 11. Reprogenix Bioscience iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 12. Reprogenix Bioscience Recent Developments and Future Plans

Table 13. Sana Biotechnology Company Information, Head Office, and Major Competitors

Table 14. Sana Biotechnology Major Business

Table 15. Sana Biotechnology iPSC-Derived Islet Cell Therapy Product and Solutions

Table 16. Sana Biotechnology iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 17. Sana Biotechnology Recent Developments and Future Plans

Table 18. Century Therapeutics Company Information, Head Office, and Major Competitors

Table 19. Century Therapeutics Major Business

Table 20. Century Therapeutics iPSC-Derived Islet Cell Therapy Product and Solutions

Table 21. Century Therapeutics iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 22. Evotec Company Information, Head Office, and Major Competitors
Table 23. Evotec Major Business
Table 24. Evotec iPSC-Derived Islet Cell Therapy Product and Solutions
Table 25. Evotec iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 26. Evotec Recent Developments and Future Plans
Table 27. Sernova Company Information, Head Office, and Major Competitors
Table 28. Sernova Major Business
Table 29. Sernova iPSC-Derived Islet Cell Therapy Product and Solutions
Table 30. Sernova iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 31. Sernova Recent Developments and Future Plans
Table 32. Aspect Biosystems Company Information, Head Office, and Major Competitors
Table 33. Aspect Biosystems Major Business
Table 34. Aspect Biosystems iPSC-Derived Islet Cell Therapy Product and Solutions
Table 35. Aspect Biosystems iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 36. Aspect Biosystems Recent Developments and Future Plans
Table 37. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 38. Novo Nordisk Major Business
Table 39. Novo Nordisk iPSC-Derived Islet Cell Therapy Product and Solutions
Table 40. Novo Nordisk iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 41. Novo Nordisk Recent Developments and Future Plans
Table 42. Allele Biotechnology Company Information, Head Office, and Major Competitors
Table 43. Allele Biotechnology Major Business
Table 44. Allele Biotechnology iPSC-Derived Islet Cell Therapy Product and Solutions
Table 45. Allele Biotechnology iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 46. Allele Biotechnology Recent Developments and Future Plans
Table 47. SCM Lifescience Company Information, Head Office, and Major Competitors
Table 48. SCM Lifescience Major Business
Table 49. SCM Lifescience iPSC-Derived Islet Cell Therapy Product and Solutions
Table 50. SCM Lifescience iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 51. SCM Lifescience Recent Developments and Future Plans
Table 52. Creative Medical Technology Company Information, Head Office, and Major

Competitors

Table 53. Creative Medical Technology Major Business

Table 54. Creative Medical Technology iPSC-Derived Islet Cell Therapy Product and Solutions

Table 55. Creative Medical Technology iPSC-Derived Islet Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 56. Creative Medical Technology Recent Developments and Future Plans

Table 57. Global iPSC-Derived Islet Cell Therapy Revenue (USD Million) by Players (2021-2026)

Table 58. Global iPSC-Derived Islet Cell Therapy Revenue Share by Players (2021-2026)

Table 59. Breakdown of iPSC-Derived Islet Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3)

Table 60. Market Position of Players in iPSC-Derived Islet Cell Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 61. Head Office of Key iPSC-Derived Islet Cell Therapy Players

Table 62. iPSC-Derived Islet Cell Therapy Market: Company Product Type Footprint

Table 63. iPSC-Derived Islet Cell Therapy Market: Company Product Application Footprint

Table 64. iPSC-Derived Islet Cell Therapy New Market Entrants and Barriers to Market Entry

Table 65. iPSC-Derived Islet Cell Therapy Mergers, Acquisition, Agreements, and Collaborations

Table 66. Global iPSC-Derived Islet Cell Therapy Consumption Value (USD Million) by Type (2021-2026)

Table 67. Global iPSC-Derived Islet Cell Therapy Consumption Value Share by Type (2021-2026)

Table 68. Global iPSC-Derived Islet Cell Therapy Consumption Value Forecast by Type (2027-2032)

Table 69. Global iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2026)

Table 70. Global iPSC-Derived Islet Cell Therapy Consumption Value Forecast by Application (2027-2032)

Table 71. North America iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 72. North America iPSC-Derived Islet Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 73. North America iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 74. North America iPSC-Derived Islet Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 75. North America iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 76. North America iPSC-Derived Islet Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 77. Europe iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 78. Europe iPSC-Derived Islet Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 79. Europe iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 80. Europe iPSC-Derived Islet Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 81. Europe iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 82. Europe iPSC-Derived Islet Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 83. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 84. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 85. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 86. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 87. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)

Table 88. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Region (2027-2032) & (USD Million)

Table 89. South America iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 90. South America iPSC-Derived Islet Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 91. South America iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 92. South America iPSC-Derived Islet Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 93. South America iPSC-Derived Islet Cell Therapy Consumption Value by

Country (2021-2026) & (USD Million)

Table 94. South America iPSC-Derived Islet Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 95. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 96. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 97. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 98. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 99. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 100. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 101. Global Key Players of iPSC-Derived Islet Cell Therapy Upstream (Raw Materials)

Table 102. Global iPSC-Derived Islet Cell Therapy Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. iPSC-Derived Islet Cell Therapy Picture
- Figure 2. Global iPSC-Derived Islet Cell Therapy Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Type in 2025
- Figure 4. Autologous iPSC-Derived Islet Cell Therapy
- Figure 5. HLA-Matched Allogeneic iPSC-Derived Islet Cell Therapy
- Figure 6. Universal Allogeneic iPSC-Derived Islet Cell Therapy
- Figure 7. Global iPSC-Derived Islet Cell Therapy Consumption Value by Cell Composition, (USD Million), 2021 & 2025 & 2032
- Figure 8. Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Cell Composition in 2025
- Figure 9. Beta Cell-Enriched Clusters
- Figure 10. Islet-Like Clusters
- Figure 11. Endocrine Subtype-Complete Islets
- Figure 12. Pancreatic Islet Organoids
- Figure 13. Global iPSC-Derived Islet Cell Therapy Consumption Value by Immune Protection Strategy, (USD Million), 2021 & 2025 & 2032
- Figure 14. Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Immune Protection Strategy in 2025
- Figure 15. Immunosuppression-Dependent Therapy
- Figure 16. Encapsulation-Protected Therapy
- Figure 17. Hypoimmune Gene-Edited Therapy
- Figure 18. Autologous Immune-Matched Therapy
- Figure 19. Global iPSC-Derived Islet Cell Therapy Consumption Value by Transplantation Site, (USD Million), 2021 & 2025 & 2032
- Figure 20. Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Transplantation Site in 2025
- Figure 21. Portal Vein or Liver Site
- Figure 22. Subcutaneous Site
- Figure 23. Intramuscular Site
- Figure 24. Omental Site
- Figure 25. Other Implantation Sites
- Figure 26. Global iPSC-Derived Islet Cell Therapy Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 27. iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Application in 2025

Figure 28. Type 1 Diabetes Picture

Figure 29. Type 2 Diabetes Picture

Figure 30. Pancreatogenic Diabetes Picture

Figure 31. Monogenic or Special Diabetes Picture

Figure 32. Preclinical Research Picture

Figure 33. Other Picture

Figure 34. Global iPSC-Derived Islet Cell Therapy Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 35. Global iPSC-Derived Islet Cell Therapy Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 36. Global Market iPSC-Derived Islet Cell Therapy Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)

Figure 37. Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Region (2021-2032)

Figure 38. Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Region in 2025

Figure 39. North America iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 40. Europe iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 41. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 42. South America iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 43. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 44. Company Three Recent Developments and Future Plans

Figure 45. Global iPSC-Derived Islet Cell Therapy Revenue Share by Players in 2025

Figure 46. iPSC-Derived Islet Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025

Figure 47. Market Share of iPSC-Derived Islet Cell Therapy by Player Revenue in 2025

Figure 48. Top 3 iPSC-Derived Islet Cell Therapy Players Market Share in 2025

Figure 49. Top 6 iPSC-Derived Islet Cell Therapy Players Market Share in 2025

Figure 50. Global iPSC-Derived Islet Cell Therapy Consumption Value Share by Type (2021-2026)

Figure 51. Global iPSC-Derived Islet Cell Therapy Market Share Forecast by Type (2027-2032)

Figure 52. Global iPSC-Derived Islet Cell Therapy Consumption Value Share by Application (2021-2026)

Figure 53. Global iPSC-Derived Islet Cell Therapy Market Share Forecast by Application (2027-2032)

Figure 54. North America iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 55. North America iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 56. North America iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 57. United States iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 58. Canada iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 59. Mexico iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 60. Europe iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 61. Europe iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 62. Europe iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 63. Germany iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 64. France iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 65. United Kingdom iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 66. Russia iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 67. Italy iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 68. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 69. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 70. Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Region (2021-2032)

Figure 71. China iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) &

(USD Million)

Figure 72. Japan iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 73. South Korea iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 74. India iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 75. Southeast Asia iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 76. Australia iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 77. South America iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 78. South America iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 79. South America iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 80. Brazil iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 81. Argentina iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 82. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 83. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 84. Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 85. Turkey iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 86. Saudi Arabia iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 87. UAE iPSC-Derived Islet Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 88. iPSC-Derived Islet Cell Therapy Market Drivers

Figure 89. iPSC-Derived Islet Cell Therapy Market Restraints

Figure 90. iPSC-Derived Islet Cell Therapy Market Trends

Figure 91. Porters Five Forces Analysis

Figure 92. iPSC-Derived Islet Cell Therapy Industrial Chain

Figure 93. Methodology

Figure 94. Research Process and Data Source

I would like to order

Product name: Global iPSC-Derived Islet Cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G25C875AEA05EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G25C875AEA05EN.html>